周五，H.C. Wainwright维持对Astria Therapeutics (NASDAQ:ATXS)的买入评级，目标价格坚持在16.00美元。该公司的关注点集中在本周早些时候关于一种竞争性特应性皮炎(AD)治疗方法的最新进展上。安进公司宣布了其OX40抗体rocatinlimab在HORIZON试验中的初步第三期结果。 研究报告显示，rocatinlimab的表现优于安慰剂，达到了所有主要 ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

特应性皮炎是最常见的湿疹类型，是一种慢性炎症性疾病，会导致皮肤过度干燥、瘙痒并伴有疼痛。中度至重度特应性皮炎患者会出现慢性症状，不可预测的发作会加剧症状，可能带来疼痛并扰乱日常生活。这些患者中几乎有一半报告出现严重瘙痒，导致反复抓挠，这会导致皮肤增厚 ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen's shares fell over 5% after updates on its Phase III immunology drug, rocatinlimab, raised investor concerns. While the ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

周三，Truist Securities维持对Amgen (NASDAQ:AMGN)股票的买入评级，目标价保持在320.00美元不变。这一决定是在Amgen披露两个主要管线项目的积极Phase 3更新之后做出的。这些项目涉及用于治疗全身性重症肌无力(gMG)的Uplizna，以及用于治疗特应性皮炎的rocatinlimab，后者是ROCKET项目在该适应症上的首次结果。 Amgen于周二报告了这些 ...

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...